Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 106 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PRE-RA Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate

NCT00282308
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Rituximab, Methotrexate, Methylprednisone, C. albicans, Tetanus toxoid adsorbed booster vaccine, 23-valent pneumococcal polysaccharide vaccine, Keyhole limpet hemocyanin
Drug · Biological
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
34
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 4, 2026, 5:19 AM EDT
Completed Phase 4 Interventional Results available

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

NCT02451748
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine, Medrol, Prednisone, Triamcinolone, Naproxen, Leflunomide, Methotrexate, humira
Other · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 4, 2026, 5:19 AM EDT
Completed Not applicable Interventional

Testing the Effectiveness of Child and Parent-Targeted Health Promotion Interventions in Pediatric Stem Cell Transplantation

NCT00760227
View directory record Official record
Conditions
Bone Marrow, Stem Cell Transplant
Interventions
Massage Therapy, Humor Therapy, Relaxation Therapy
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
3
States / cities
Columbus, Ohio • Philadelphia, Pennsylvania • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 28, 2011 · Synced Sep 4, 2026, 5:19 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

NCT03361735
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Leuprolide Acetate, Goserelin Acetate, Stereotactic Body Radiation Therapy, Radium Ra 223 Dichloride, Laboratory Biomarker Analysis, Degarelix
Drug · Radiation · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 4, 2026, 5:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

NCT00254293
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept or Placebo (both as IV & SC solution), Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
5
States / cities
Orlando, Florida • Atlanta, Georgia • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Sep 4, 2026, 5:19 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients

NCT01061736
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, Placebo (for sarilumab), Methotrexate, Folic Acid
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
45
States / cities
Anniston, Alabama • Birmingham, Alabama • Gilbert, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Sep 4, 2026, 5:19 AM EDT
Terminated Phase 3 Interventional Results available

An Open Label Study for Participants With Rheumatoid Arthritis

NCT01215942
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY2127399
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
127
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Sep 4, 2026, 5:19 AM EDT
Active, not recruiting Not applicable Interventional

Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)

NCT05040087
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Intensification of diabetes medication based largely on HbA1c levels, Intensification of diabetes medication based on glucose levels
Other
Lead sponsor
Foundation for Atlanta Veterans Education and Research, Inc.
Other
Eligibility
40 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 4, 2026, 5:19 AM EDT
Completed Phase 4 Interventional

Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease

NCT01893996
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Disease
Interventions
Adalimumab, Placebo
Drug
Lead sponsor
Jonathan Graf
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Sep 4, 2026, 5:19 AM EDT
Completed No phase listed Observational

Multi-academic Center Study of Xofigo Patients

NCT03419442
View directory record Official record
Conditions
Prostate Cancer, Castration Resistant
Interventions
Xofigo, Taxotere, Jevtana
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 4, 2026, 5:19 AM EDT
Completed Not applicable Interventional

High Dose Chemotherapy and Autologous Transplant for Neuroblastoma

NCT01526603
View directory record Official record
Conditions
Neuroblastoma
Interventions
Carboplatin, Autologous stem cell infusion, Granulocyte colony stimulating factor, Radiation therapy, Isotretinoin (13-cis-retinoic acid), Melphalan, Etoposide
Drug · Biological · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 30 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Sep 4, 2026, 5:19 AM EDT
Not yet recruiting Not applicable Interventional

Expanding Genetic Access for Prostate Cancer Survivors

NCT07618520
View directory record Official record
Conditions
Prostate Cancer Patients, Hereditary Cancer, Genetic Testing
Interventions
Print Genetic Education Guide, Digital Guide Genetic Education Guide, Enhanced Usual Care
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 4, 2026, 5:19 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Baricitinib Curative Repression of HIV-1

NCT07209267
View directory record Official record
Conditions
HIV Infection, HIV
Interventions
Antiretroviral Therapy (ART), Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 4, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

NCT03093428
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radium-223, Pembrolizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 4, 2026, 5:19 AM EDT
Completed Not applicable Interventional

Preventing Opioid Use Among Justice-involved Youth as They Transition to Adulthood Leveraging Safe Adults (LeSA)

NCT04678960
View directory record Official record
Conditions
Opioid Use, Substance Use
Interventions
Trust-based Relational Intervention Training, Trust-based Relational Intervention In-Home Structured Coaching, Trust-based Relational Intervention In-Home Responsive Coaching
Behavioral
Lead sponsor
Texas Christian University
Other
Eligibility
15 Years to 20 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Chicago, Illinois • Grafton, Illinois • Harrisburg, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 4, 2026, 5:19 AM EDT
Terminated Phase 1 Interventional

Study of GS-0272 in Participants With Rheumatoid Arthritis

NCT06031415
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GS-0272, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Glendale, California • Palo Alto, California • Upland, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 4, 2026, 5:19 AM EDT
Active, not recruiting No phase listed Observational

Anti-obesity Pharmacotherapy and Inflammation

NCT05756764
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
35 Years to 60 Years
Enrollment
30 participants
Timeline
2023 – 2026
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 4, 2026, 5:19 AM EDT
Recruiting Phase 1 Interventional

Imaging of Lymphatic Vessels in People With Rheumatoid Arthritis (RA)

NCT05197530
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Indocyanine green, MultiSpectral Imaging System
Drug · Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 4, 2026, 5:19 AM EDT
Completed Not applicable Interventional

Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA

NCT05562037
View directory record Official record
Conditions
Angina, Stable, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Interventions
Stepped Care
Other
Lead sponsor
Peter Lindenauer, MD
Other
Eligibility
60 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Pittsfield, Massachusetts • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 4, 2026, 5:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Duration of Immune Response to Influenza Vaccination in Patients With RA

NCT02311855
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Influenza vaccine
Biological
Lead sponsor
Bassett Healthcare
Other
Eligibility
40 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 4, 2026, 5:19 AM EDT
Withdrawn Not applicable Interventional

Hearing Resources and Outcomes in the Emergency Department (HERO-ED)

NCT03053531
View directory record Official record
Conditions
Hearing Loss
Interventions
PockeTalker" Hearing Assistive Device (HAD)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
75 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Sep 4, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

NCT02346526
View directory record Official record
Conditions
Prostate Cancer, Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer Metastatic to Bone
Interventions
Blood Tests, CT scan, FACBC PET/MRI in a subset of participants, Radium-223 dichloride, bone scan
Procedure · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Sep 4, 2026, 5:19 AM EDT
Recruiting Not applicable Interventional

Interactive Computer-adaptive Chronic Kidney Disease Education Program

NCT06364358
View directory record Official record
Conditions
Chronic Kidney Diseases, Hypertension
Interventions
Computerized CKD Education, Usual Hospital Care
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 4, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB

NCT02748317
View directory record Official record
Conditions
Lower Urinary Tract Symptoms
Interventions
Lactobacillus rhamnosus GG
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 4, 2026, 5:19 AM EDT